|
|
||||||||||||||
|
|
|||||||||||||||
Correspondence to:
Correspondence to:
J-F Fléjou
Service dAnatomie Pathologique, CHU Saint-Antoine, Assistance PubliqueHôpitaux de Paris, 184 rue du Faubourg Saint-Antoine, F-75571, Paris, Cedex 12, France;jean-francois.flejou{at}sat.ap-hop-paris.fr
ABSTRACT
Barretts oesophagus is a premalignant condition that predisposes to the development of oesophageal adenocarcinoma. It is detected on endoscopy and confirmed histologically by the presence in the lower oesophagus of a metaplastic mucosa, the so-called specialised epithelium, which resembles incomplete intestinal metaplasia in the stomach. These similarities with incomplete intestinal metaplasia are present on histology, mucin histochemistry, and immunohistochemistry with various differentiation markers (cytokeratins and MUC antigens). On morphology, the carcinogenetic process of Barretts mucosa progresses through increasing grades of epithelial dysplasia. Dysplasia, a synonym of intraepithelial neoplasia, is the only marker that can be used at the present time to delineate a population of patients at high risk of cancer. Among the numerous molecular events that have been shown to play a role in the neoplastic transformation of Barretts mucosa, only changes in DNA ploidy, increased proliferation, and alterations of the p53 gene have been suggested to be of potential help in the surveillance of patients.
Abbreviations: CK, cytokeratin; HGD, high grade dysplasia; LGD, low grade dysplasia
Keywords: Barretts oesophagus; dysplasia; metaplasia; oesophageal cancer; p53 protein
This article has been cited by other articles:
![]() |
L. Kleinberg and A. A. Forastiere Chemoradiation in the Management of Esophageal Cancer J. Clin. Oncol., September 10, 2007; 25(26): 4110 - 4117. [Abstract] [Full Text] [PDF] |
||||
![]() |
I Tischoff, U R Hengge, M Vieth, C Ell, M Stolte, A Weber, W E Schmidt, and A Tannapfel Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma Gut, August 1, 2007; 56(8): 1047 - 1053. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Roman, A. Petre, A. Thepot, A. Hautefeuille, J.-Y. Scoazec, F. Mion, and P. Hainaut Downregulation of p63 upon exposure to bile salts and acid in normal and cancer esophageal cells in culture Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G45 - G53. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Lagarde, F. J. W. ten Kate, D. J. Richel, G. J. A. Offerhaus, and J. J. B. van Lanschot Molecular Prognostic Factors in Adenocarcinoma of the Esophagus and Gastroesophageal Junction Ann. Surg. Oncol., February 1, 2007; 14(2): 977 - 991. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Boerboom, L. D. White, S. Dalle, J. Courty, and J. S. Richards Dominant-Stable {beta}-Catenin Expression Causes Cell Fate Alterations and Wnt Signaling Antagonist Expression in a Murine Granulosa Cell Tumor Model Cancer Res., February 15, 2006; 66(4): 1964 - 1973. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |